Immunic Inc (NAS:IMUX)
$ 1.3 0.02 (1.56%) Market Cap: 117.10 Mil Enterprise Value: 20.02 Mil PE Ratio: 0 PB Ratio: 1.40 GF Score: 43/100

Immunic Inc Celiac Disease R&D Webcast Transcript

Feb 09, 2023 / 04:00PM GMT
Release Date Price: $2.03 (-9.38%)
Jessica Breu
Immunic, Inc. - Head of IR & Communications

Good morning, everybody. I would like to welcome you to Immunic Celiac Disease Research and Development webcast to discuss current pathways for drug development and persistent disease activity despite gluten-free diet as the unmet medical need. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's webcast.

As always, in the beginning of our webcast, I will walk you through a couple of organizational items first. Please note that all participants will be in listen-only mode, and this event is being recorded. During and after today's presentation, there will be an opportunity to ask questions. (Operator Instructions).

Before we begin, I also would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate, or words with a similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot